Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
0
institutions
52-week range
$0.03 β $0.11
47% from low
Exchange
OTC Link
CS
HEPION PHARMS INC
No one on the platform currently holds HEPA.
No tracked institution reports a position in HEPA as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-03-18 | 1-for-50reverse |
| 2023-05-11 | 1-for-20reverse |
| 2019-06-03 | 1-for-70reverse |
| 2018-05-29 | 1-for-8reverse |
No one on the platform has traded HEPA yet.
$HEPA The new 10Q is out! "We had no revenues during the six months ended June 30, 2026 and 2025, because we have not commercialized any of our medical diagnostic products and we do not expect to have such products for several years, if at all."
View on StockTwits β$HEPA CEO purchased 2,000,000 shares at $0.05 for a total of $100,000. Stetz Gary S. now owns 3,250,000 shares. https://ceo-buys.com
View on StockTwits β$HEPA OTC stock now... insiders are busy. Vincent S. LoPriore (Executive Chairman) Buys 20M Shares @ $0.03 | Michael J. Purcell (Director) Buys 4M Shares @ $0.03 | Gary S. Stetz II (Director) Buys 1M Shares @ $0.03 (Form 4)
View on StockTwits β$HEPA This people have been destroying shareholders portfolios and taking their money for many many years. They have changed their names many times. They have reverse split so many times, that they canβt do it anymore. They shouldβve been investigated a long time ago.
View on StockTwits β$HEPA HEPA shareholders may want to take a closer look at the May 2025 sale of Rencofilstat to Panetta Partners. Rencofilstat had been Hepionβs lead drug asset, yet the company transferred the patents, know-how, clinical-trial data and drug product for nominal upfront consideration. Shareholders received CVRs with maximum aggregate milestone payments of $4.5 million if the drug eventually achieves FDA approval and major sales milestones. Panetta is associated with Gabriele Cerrone, who has been described as a co-founder of Hepion. I am not alleging wrongdoing, but I think shareholders should ask whether there was an independent valuation, market check, competing bids or a fairness review. It would also be useful to know how the Board evaluated any potential conflicts of interest. A Delaware Section 220 books-and-records request could potentially provide answers. Are any U.S. HEPA shareholders or attorneys looking into this transaction?
View on StockTwits β$HEPA https://www.sec.gov/Archives/edgar/data/1583771/000214683826000001/xslSCHEDULE_13D_X02/primary_doc.xml
View on StockTwits β$HEPA The balls on this bull are swinging big untouched Gem of the stock market why do you think they kept so much secret im invested with a few bucks
View on StockTwits β$HEPA Why would the BOD approve the sale of Rencofilstat before releasing the data to shareholders? The CVR'S are worthless Brancaccio just gave it away to Panetta partners where Brancaccio's buddy Gabriel Cerrone is at. How many companies have Brancaccio and Cerrone been involved with together and that who the BOD approves to give away Rencofilstat to. Their is no way all of this could be legal what a bunch of thieves.
View on StockTwits β$HEPA Maybe someone should come in and buy 500k sharesπ how could their be shares for sale if there really is only like 11.6 million in the float would be a good one for SEC and Finra to watch
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $0 | β | $-472.00 | $-472.00β$-472.00 | β | 1 |
| 2027 | $0 | β | $-468.00 | $-468.00β$-468.00 | β | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 4 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-200.00 | $-0.08 | +100.0% |
| 2026-05-14 | $-200.00 | $-0.07 | +100.0% |
| 2025-04-08 | $-98.50 | $-11.12 | +88.7% |
| 2024-11-14 | $-95.00 | $-36.00 | +62.1% |
| $89M |
| β |
| NIVFNewGenIvf Group Limited | $0.53 | -2.87% | $101199 | β |
| PTPIPetros Pharmaceuticals, Inc. | $0.00 | -11.76% | $127117 | β |
Source: Financial Modeling Prep Β· peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.